Erste Group analyst Hans Engel downgraded Amgen (AMGN) to Hold from Buy, saying the company’s sales growth will likely decline in 2026 and 2027. Amgen’s growth is lower than competitors, the analyst tells investors in a research note. Erste sees limited share upside potential in the medium term.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Amgen to invest additional $300M in U.S. manufacturing network
- Amgen price target lowered to $340 from $351 at Guggenheim
- Amgen Earnings Call Highlights Growth Engines, Tax Risk
- Analyst Reiterates Buy on Amgen After Strong Q1 2026, Raised Guidance and Growing Confidence in MariTide Pipeline
- Amgen Price Target Raised to $425 as Strong Execution and Expanding Pipeline Underpin Maintained Buy Rating